AVIR Stock Summary and Trading Ideas (Atea Pharmaceuticals | NASDAQ:AVIR)

Atea Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.

Atea Pharmaceuticals trades on the NASDAQ stock market under the symbol AVIR.

As of October 20, 2026, AVIR stock price climbed to $4.47 with 280,995 million shares trading.

AVIR has a beta of 1.25, meaning it tends to be more sensitive to market movements. AVIR has a correlation of 0.06 to the broad based SPY ETF.

AVIR has a market cap of $358.11 million. This is considered a Small Cap stock.

In the last 3 years, AVIR traded as high as $6.45 and as low as $2.46.

The top ETF exchange traded funds that AVIR belongs to (by Net Assets): VTI, IWM, VXF, IWN, DFAS.

AVIR has outperformed the market in the last year with a return of +45.9%, while the SPY ETF gained +16.9%. However, in the most recent history, AVIR shares have underperformed the stock market with its stock returning -8.3% in the last 3 month period and -13.0% for the last 2 week period, while SPY has returned +3.7% and -0.7%, respectively.

AVIR support price is $4.23 and resistance is $4.55 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AVIR shares will trade within this expected range on the day.